7th Myeloid-Directed Therapies Summit

The Only Industry-Dedicated Summit for Advancing Myeloid Cell Therapies in Oncology, Inflammation and Beyond...

Uniting leading experts from pharma, biotech, and academia, the 7th Myeloid-Directed Therapies Summit is the definitive event for anyone developing macrophage- and neutrophil-targeted therapies. As the field pushes beyond T-cells, this forum dives into myeloid reprogramming, cell state heterogeneity, and translational challenges to unlock next-generation immune modulation.

With breakthrough insights from Eli Lilly, AbbVie, Pfizer, AstraZeneca, and Faron Pharmaceuticals, and cutting-edge academic labs, this is your opportunity to explore clinical case studies, dissect failed monotherapy lessons, and gain clarity on patient stratification, trial design, and combination strategies.

So, why now?

From solid tumor immunotherapy to fibrotic disease, myeloid biology is proving pivotal. Yet many programs stall due to poor translation, limited biomarkers, and inadequate models. This Summit brings the community together to tackle these hurdles head-on, and propel the next wave of successful myeloid therapeutics forward.

URLs:
Website: https://go.evvnt.com/3229096-0?pid=2874
Brochure: https://go.evvnt.com/3229096-3?pid=2874

Category: Conferences | Health

Prices:
Drug Developer Price - Conference + 2 Workshops: USD 4197.00,
Drug Developer Price - Conference + 1 Workshop: USD 3598.00,
Drug Developer Price - Conference Only: USD 2999.00,
Academics and Small Biotechs Price - Conference + 2 Workshops: USD 3597.00,
Academics and Small Biotechs Price - Conference + 1 Workshop: USD 3098.00,
Academics and Small Biotechs Price - Conference Only: USD 2599.00,
Vendor Price - Conference + 2 Workshops: USD 5097.00,
Vendor Price - Conference + 1 Workshop: USD 4398.00,
Vendor Price - Conference Only: USD 3699.00

Speakers: Alexander Barron Principal Scientist II Novartis, Amira Barkal Principal Founder and Chief Executive Officer Pheast Therapeutics, Anna Galkin Chief Scientific Officer Axelia Oncology, Debashis Sahoo Associate Professor University of California San Diego, Dmitry Gabrilovich Executive Director, Chief Scientist, Cancer AstraZeneca, Evgeniy Eruslanov Associate Professor University of Pennsylvania, Haitao Guo Senior Scientist Abbvie, Jean Tchervenkov Professor, Transplant Surgeon McGill University, Jennifer Guerriero Lead Investigator, Assistant Professor Brigham and Women's Hospital, Jonathan Lartigue Assistant Professor of Surgery McGill University Health Centre, Juho Jalkanen Chief Executive Officer Faron Pharmaceuticals, Leslie Nangle Vice President, Research aTyr Pharma Inc., Maija Hollmen Chief Scientific Officer Faron Pharmaceuticals, Marc Wadsworth II Senior Principal Scientist Pfizer, Mattin Treder CSO LTZ Therapeutics, Miriam Merad Dean, Translational Research and Therapeutic Innovation Icahn School of Medicine at Mount Sinai, Nir Ben Chetrit Assistant Professor Weil Cornell Medicine, Shweta Joshi Principal Investigator University of California San Diego, Tatiana Novobrantseva Chief Scientific Officer NextPoint Therapeutics, Thomas Fabre Senior Principal Scientist Pfizer, Yupeng (David) He Principal Scientist and Project Leader Abbvie